Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Lung Cancer Excellence Forum

Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
Tina Cascone, MD, PhD, MD Anderson Cancer Center
Videos
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Surgery and Adjuvant Nivolumab Improves EFS in NSCLC
10/23/2023
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses...
10/23/2023
Oncology
Edward Garon, MD, University of California, Los Angeles
Videos
Immuno-Oncology Alone for Patients With Lung Cancer and High PD-L1 Expression
05/18/2023
At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.
At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.
At the Great Debates and Updates...
05/18/2023
Oncology
Patrick Forde, MD, Johns Hopkins Medical Institute, Baltimore, MD
Videos
Chemotherapy Plus Immuno-Oncology for Lung Cancer With High PD-L1 Expression
05/18/2023
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.
At the 2023 Great Debates and...
05/18/2023
Oncology
Lyudmila Bazhenova, MD, University of California San Diego
Videos
The Importance of Biomarker Testing for Patients With NSCLC
01/05/2023
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.
Edward Garon, MD, and Lyudmila...
01/05/2023
Oncology
Edward Garon, MD, University of California Los Angeles
Videos
Frontline Management of NSCLC After Approval of Durvalumab Plus Tremelimumab and Chemotherapy
12/22/2022
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.
Edward Garon, MD, and Lyudmila...
12/22/2022
Oncology
Sharyn Katz, MD, MTR, Associate Professor at the University of Pennsylvania Perelman School of Medicine
Videos
Radiology of COVID: Dealing With Diagnostic Ambiguity
09/28/2022
Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.
Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.
Sharyn Katz, MD, MTR, provides...
09/28/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania
Videos
Immune Checkpoint Inhibitors Improve Treatment Outcomes in Malignant Pleural Mesothelioma
09/22/2022
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology at the Abramson Cancer Center at the University of Pennsylvania
Videos
Potential Impact of Immune Checkpoint Inhibitors in Thymic Malignancies
09/22/2022
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology
Edward Garon, MD, MS, David Geffen School of Medicine, University of California Los Angeles
Videos
Dr Edward Garon on the Basics of Immunotherapy in Lung Cancer
09/14/2022
Edward Garon, MD, MS, provides an overview on the basics of immunotherapy for NSCLC and SCLC, a topic he presented at the virtual 2022 GDU Lung Cancers meeting.
Edward Garon, MD, MS, provides an overview on the basics of immunotherapy for NSCLC and SCLC, a topic he presented at the virtual 2022 GDU Lung Cancers meeting.
Edward Garon, MD, MS, provides...
09/14/2022
Oncology

Advertisement

Section Editor

cjl
Corey J. Langer, MD
Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement